Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Blood (2023) 141 (8): 917–929.

https://doi.org/10.1182/blood.2022016846

Published: 2023

Includes: Supplemental data

Journal Articles

Canonical Thrombopoietin Receptor Mutants in Myeloproliferative Neoplasms Rely Differently on the Extracellular Domain of the Receptor but Share Similar Mechanisms of Inactivation: An Open Field for the Development of New Therapies

Gabriel Levy, Nicolas Papadopoulos, Christian Pecquet, Jean-Philippe Defour, Emilie Leroy, Nabih Maslah, Bruno Cassinat, Steven Smith, Stefan N Constantinescu

Blood (2022) 140 (Supplement 1): 8736–8737.

https://doi.org/10.1182/blood-2022-168663

Published: 2022

Journal Articles

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491

Gabriel Levy, Serge Carillo, Benjamin Papoular, Bruno Cassinat, Jean-Marc Zini, Emilie Leroy, Leila N. Varghese, Ilyas Chachoua, Jean-Philippe Defour, Steven O. Smith, Stefan N. Constantinescu

Blood (2020) 135 (12): 948–953.

https://doi.org/10.1182/blood.2019003240

Published: 2020

Includes: Supplemental data

Journal Articles

Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants

Blood (2019) 133 (25): 2669–2681.

https://doi.org/10.1182/blood-2018-09-874578

Published: 2019

Includes: Supplemental data

Journal Articles

Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms

Cristina Mambet, Olga Babosova, Jean-Philippe Defour, Emilie Leroy, Laura Necula, Oana Stanca, Aurelia Tatic, Nicoleta Berbec, Daniel Coriu, Monika Belickova, Barbora Kralova, Lucie Lanikova, Jitka Vesela, Christian Pecquet, Pascale Saussoy, Violaine Havelange, Carmen C. Diaconu, Vladimir Divoky, Stefan N. Constantinescu

Blood (2018) 132 (25): 2695–2699.

https://doi.org/10.1182/blood-2018-04-843060

Published: 2018

Includes: Supplemental data

Journal Articles

JAK2 R1063H Variant Enhances V617F Constitutive Signaling and Favors Development of Essential Thrombocythemia with Increased Hemoglobin and Neutrophils

Cristina Mambet, MD, Jean-Philippe Defour, BPharm, PhD, Olga Babosova, M.Sc., Emilie Leroy, Laura Necula, PhD, Oana Stanca, MD, Aurelia Tatic, MD, Daniel Coriu, MD, Monika Belickova, PhD, Barbora Kralova, MSc, Lucie Lanikova, PhD, Pascale Saussoy, Violaine Havelange, Carmen C. Diaconu, PhD, Vladimir Divoky, PhD, Stefan N Constantinescu, MD

Blood (2018) 132 (Supplement 1): 3066.

https://doi.org/10.1182/blood-2018-99-117019

Published: 2018

Journal Articles

Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy

Blood (2018) 132 (Supplement 1): 4.

https://doi.org/10.1182/blood-2018-99-118348

Published: 2018

Journal Articles

An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L

Fabrizia Favale, Kahia Messaoudi, Leila N. Varghese, Siham Boukour, Christian Pecquet, Vitalina Gryshkova, Jean Philippe Defour, Roxana-Irina Albu, Olivier Bluteau, Paola Ballerini, Guy Leverger, Isabelle Plo, Najet Debili, Hana Raslova, Remi Favier, Stefan N. Constantinescu, William Vainchenker

Blood (2016) 128 (26): 3146–3158.

https://doi.org/10.1182/blood-2016-06-722058

Published: 2016

Includes: Supplemental data

Journal Articles

Crispr/Cas9 Engineered 61bp Deletion in the Calr Gene of Mice Leads to Development of Thrombocytosis

Thomas Balligand, MD, Younes Achouri, PhD, Ilyas Chachoua, MSc, Christian Pecquet, PhD, Jean-Philippe Defour, BPharm,, Stefan N. Constantinescu

Blood (2016) 128 (22): 4274.

https://doi.org/10.1182/blood.V128.22.4274.4274

Published: 2016

Journal Articles

Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants

Ilyas Chachoua, Christian Pecquet, Mira El-Khoury, Harini Nivarthi, Roxana-Irina Albu, Caroline Marty, Vitalina Gryshkova, Jean-Philippe Defour, Gaëlle Vertenoeil, Anna Ngo, Ann Koay, Hana Raslova, Pierre J. Courtoy, Meng Ling Choong, Isabelle Plo, William Vainchenker, Robert Kralovics, Stefan N. Constantinescu

Blood (2016) 127 (10): 1325–1335.

https://doi.org/10.1182/blood-2015-11-681932

Published: 2016

Includes: Supplemental data

Journal Articles

Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients

Blood (2016) 127 (3): 333–342.

https://doi.org/10.1182/blood-2015-07-661983

Published: 2016

Includes: Supplemental data

Journal Articles

Thrombopoietin Activates STAT2 Inducing Type I Interferon Effects and Gene Expression: Implications for in Vivo Tpo Treatment and for Myeloproliferative Neoplasms

Stefan N Constantinescu, MD PhD Prof., Jean-Philippe Defour, BPharm,, Celine Mouton, Isabelle Plo, William Vainchenker, MD PhD, Jean-Luc Villeval, PhD, Thomas Michiels, MD PhD, Judith Staerk, Christian Pecquet, PhD

Blood (2014) 124 (21): 820.

https://doi.org/10.1182/blood.V124.21.820.820

Published: 2014

Journal Articles

Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Blood (2014) 124 (21): 1823.

https://doi.org/10.1182/blood.V124.21.1823.1823

Published: 2014

Journal Articles

Controlling Thrombopoietin Receptor Dimerization, Orientation and Activation Via Tryptophan 515

Jean-Philippe Defour, BPharm, Miki Itaya, MSc., Vitalina Gryshkova, PhD, Ian Brett, MSc., Christian Pecquet, PhD, Takeshi Sato, PhD, Steven O. Smith, PhD, Stefan N. Constantinescu, MD, PhD

Blood (2012) 120 (21): 3449.

https://doi.org/10.1182/blood.V120.21.3449.3449

Published: 2012

Journal Articles

Combination Treatment with JAK2 and PI3K Inhibitors in Myeloproliferative Neoplasms

Meng Ling Choong, PhD, Christian Pecquet, PhD, Shi Jing Tai, Jacklyn WY Yong, PhD, Vishal Pendharkar, SiFang Wang, Jean-Philippe Defour, BPharm, Carmen C. Diaconu, PhD, Kanda Sangthongpitag, PhD, Jean-Luc Villeval, PhD, William Vainchenker, MD, PhD, Stefan N. Constantinescu, MD, PhD, May Ann Lee, PhD

Blood (2012) 120 (21): 180.

https://doi.org/10.1182/blood.V120.21.180.180

Published: 2012

Journal Articles

Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes

Christian Pecquet, Carmen C. Diaconu, Judith Staerk, Michael Girardot, Caroline Marty, Yohan Royer, Jean-Philippe Defour, Alexandra Dusa, Rodolphe Besancenot, Stephane Giraudier, Jean-Luc Villeval, Laurent Knoops, Pierre J. Courtoy, William Vainchenker, Stefan N. Constantinescu

Blood (2012) 119 (20): 4625–4635.

https://doi.org/10.1182/blood-2011-08-372524

Published: 2012

Includes: Supplemental data

NARROW

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

Canonical Thrombopoietin Receptor Mutants in Myeloproliferative Neoplasms Rely Differently on the Extracellular Domain of the Receptor but Share Similar Mechanisms of Inactivation: An Open Field for the Development of New Therapies

MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491

Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants

Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms

JAK2 R1063H Variant Enhances V617F Constitutive Signaling and Favors Development of Essential Thrombocythemia with Increased Hemoglobin and Neutrophils

Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy

An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L

Crispr/Cas9 Engineered 61bp Deletion in the Calr Gene of Mice Leads to Development of Thrombocytosis

Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants

Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients

Thrombopoietin Activates STAT2 Inducing Type I Interferon Effects and Gene Expression: Implications for in Vivo Tpo Treatment and for Myeloproliferative Neoplasms

Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Controlling Thrombopoietin Receptor Dimerization, Orientation and Activation Via Tryptophan 515

Combination Treatment with JAK2 and PI3K Inhibitors in Myeloproliferative Neoplasms

Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only